Coronary interventions Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions Verheye S, Costa R, Schofer J, Ormiston J, Maeng M, Dudek D, Skurk C, Botelho R, Costa J, Chamié D, Abizaid An, Boersma E, Abizaid A October 18, 2019 | 10.4244/EIJ-D-18-00292
Coronary interventions Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial Abizaid A, Kedev S, Kedhi E, Talwar S, Erglis A, Hlinomaz O, Masotti M, Fath-Ordoubadi F, Lemos P, Milewski K, Botelho R, Costa R, Bangalore S December 7, 2018 | 10.4244/EIJ-D-18-00762
Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Perin M, Seth A, Botelho R, Serruys P June 19, 2015 | 10.4244/EIJY15M05_06
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
Trials Book Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years (The Trials book is supported by Biotronik) December 13, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019